Secretory leukocyte protease inhibitor: inhibition of human immunodeficiency virus-1 infection of monocytic THP-1 cells by a newly cloned protein
作者:Nancy R Shine、Susan C Wang、Krystyna Konopka、Elizabeth A Burks、Nejat Düzgüneş、Christian P Whitman
DOI:10.1016/s0045-2068(02)00008-1
日期:2002.8
The ability of the salivary protein, secretory leukocyte protease inhibitor (SLPI), to inhibit human immunodeficiency virus-1 (HIV-1) infection in vitro has been reported previously and has led to the suggestion that SLPI may be partially responsible for the low oral transmission rate of HIV-1. However, results contradictory to these findings have also been published. These discrepancies can be attributed
唾液蛋白分泌型白细胞蛋白酶抑制剂(SLPI)在体外抑制人免疫缺陷病毒1(HIV-1)感染的能力已有报道,并提示SLPI可能部分归因于低口服HIV-1的传播率。但是,与这些发现相矛盾的结果也已经发表。这些差异可以归因于许多因素,从巨噬细胞对HIV感染的易感性变化到市售SLPI制剂的质量。为了解决这些差异并进一步研究SLPI的潜在抗HIV-1活性,使用人单核THP-1细胞检查了从合成基因表达的纯化和重新折叠的蛋白。与使用市售SLPI制剂观察到的结果相反,这种新克隆的SLPI减少了分化的THP-1细胞中的HIV-1(Ba-L)感染。有趣的是,尽管这两种蛋白显示出不同的抗HIV作用,但它们具有可比的抗蛋白酶活性。将THP-1细胞系鉴定为支持HIV复制的系统,可通过制备大量现成的SLPI加以抑制,这为彻底研究抗HIV的分子和结构基础奠定了基础SLPI的活动。